LEVITRA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug LEVITRA contains one active pharmaceutical ingredient (API):

1	Vardenafil UNII 5M8S2CU0TS - VARDENAFIL HYDROCHLORIDE
	Vardenafil is a potent and selective inhibitor of the cGMP specific phosphodiesterase type 5 (PDE5), the most prominent PDE in the human corpus cavernosum. Vardenafil is an oral therapy for the improvement of erectile function in men with erectile dysfunction. In the natural setting, i.e. with sexual stimulation it restores impaired erectile function by increasing blood flow to the penis.
	Read more about Vardenafil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LEVITRA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04BE09	Vardenafil	G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BE Drugs used in erectile dysfunction
Discover more medicines within G04BE09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4290T, 4302K
BR	Câmara de Regulação do Mercado de Medicamentos	515601309111214, 515601310111214, 515601312112218, 515601313119216, 538912050014413, 538912050014513, 538912050014813, 538912050014913, 538912050015013, 538916090027203
CA	Health Products and Food Branch	02250470, 02250489
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29583-01-11, 29584-01-11, 29645-02-11, 29900-07-11
EE	Ravimiamet	1126325, 1126336, 1126347, 1126358, 1126369, 1126370, 1126381, 1126392, 1126404, 1126415, 1126426, 1126437, 1492545, 1492556, 1492567, 1526521, 1605776, 1605787, 1605798
ES	Centro de información online de medicamentos de la AEMPS	03248005, 03248009IP, 03248010, 03248010IP1, 03248010IP2, 03248010IP3, 03248010IP5, 03248011IP, 03248011IP2
GB	Medicines & Healthcare Products Regulatory Agency	147669, 147671, 186803, 379919, 379921, 43612, 43620, 43621, 43631, 43632
HK	Department of Health Drug Office	51744, 51745, 51746, 61207
IL	מִשְׂרַד הַבְּרִיאוּת	4681, 4682, 4683, 6916, 6950
IT	Agenzia del Farmaco	035734122
LT	Valstybinė vaistų kontrolės tarnyba	1011759, 1011760, 1011761, 1011762, 1011763, 1029412, 1029413, 1029414, 1029415, 1032065, 1032066, 1032067, 1056529, 1056530, 1056531, 1063710, 1063715, 1063718, 1063720
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	214M2002
NL	Z-Index G-Standaard, PRK	69191, 69205, 69213
NZ	Medicines and Medical Devices Safety Authority	10652, 10653, 10654, 14174
PL	Rejestru Produktów Leczniczych	100113741, 100113758, 100113764, 100230671
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63869001, W63869002, W63869003, W63869004, W63870001, W63870002, W63870003, W63870004, W63871001, W63871002, W63871003, W63871004
SG	Health Sciences Authority	12317P, 12318P, 12319P, 14084P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699546092444, 8699546092451, 8699546092468, 8699546092475
US	FDA, National Drug Code	0173-0829, 0173-0830, 0173-0831, 55289-193
ZA	Health Products Regulatory Authority	36/7.1.5/0515, 36/7.1.5/0516, 36/7.1.5/0517, 44/7.1.5/1049